Excreted Unchanged %
Hepatic
Half-Life (Normalesrd) Hours
2-3/5.8
Plasma Protein Binding %
95
Volume Of Distribution L/Kg
5.0
Dose For Normal Renal Function
5.0 mg q8h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Caccia S, Vigano GL, Mingardi G, Garattini S, Gammans RE, Placchi M, et al. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokinet. 1988; 14: 171-7. [PMID: 3370902] / Dommisse CS, DeVane CL. Buspirone: a new type of anxiolytic. Drug Intell Clin Pharm. 1985; 19: 624-8. [PMID: 2864225] / Eison AS, Temple DL Jr. Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med. 1986; 80: 1-9. [PMID: 2870639] / Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. Am J Med. 1986; 80: 41-51. [PMID: 3515929] / Goa KL, Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs. 1986; 32: 114-29. [PMID: 2874976] / Gulyassy PF, Depner TA. Impaired binding of drugs and endogenous ligands in renal diseases. Am J Kidney Dis. 1983; 2: 578-601. [PMID: 6342372] / Pecknold JC. A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Drug Saf. 1997; 16: 118-32. [PMID: 9067123]